A fast reverse-phase high performance liquid chromatographic tandem mass spectrometry assay for the quantification of clindamycin in plasma and saliva using a rapid resolution package

被引:12
作者
Catena, Esther [1 ]
Perez, Guiomar [1 ]
Sadaba, Belen [1 ]
Ramon Azanza, Jose [1 ]
Angel Campanero, Miguel [1 ]
机构
[1] Univ Navarra, Univ Hosp, Clin Invest Unit, Navarra 31080, Spain
关键词
Clindamycin; Therapeutic drug monitoring; Saliva; Pharmacokinetics; SERUM;
D O I
10.1016/j.jpba.2009.02.005
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A new method for the quantitative analysis of clindamycin in human plasma and saliva by liquid chromatography/electrospray ionisation tandem mass spectrometry (LC/ESI-MS/MS) has been developed using a rapid resolution C18 column (2.1 mm x 30 mm x 3.5 mu m). A simple deproteinization procedure was applied to the samples before analysis. Multiple reaction monitoring (MRM) mode of precursor-product ion transitions for clindamycin (425.1/126.1) and the internal standard, lincomycin (407.2/126.0) was used. Chromatographic separation was achieved at 0.6 ml/min in less than 1.5 min, with improved peak resolution and sensitivity between drug and internal standard. The assay exhibited a linear dynamic range between 0.05 and 15.0 mu g/ml and gave a determination coefficient of 0.991 or better. The limit of quantification of the method was 10 ng/ml in both biological samples. Intra-day and inter-day precision ranged from 7.5% to 11.5%. Good accuracy was observed for both the intra-day and inter-day assays (R.S.D. below +/-4%). The suitability of the developed method for the analysis of clindamycin in plasma and saliva samples was demonstrated by the measure of clindamycin in samples taken up to 6 h after oral and intravenous administration of this drug in infectious patients. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:649 / 654
页数:6
相关论文
共 17 条
[1]  
[Anonymous], 2001, Guidance for industry, bioanalytical method validation
[2]   Community-acquired pneumonia in adults: Guidelines for management [J].
Bartlett, JG ;
Breiman, RF ;
Mandell, LA ;
File, TM .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :811-838
[3]   Determination of clindamycin in animal plasma by high-performance liquid chromatography combined with electrospray ionization mass spectrometry [J].
Cherlet, M ;
Croubels, S ;
De Backer, P .
JOURNAL OF MASS SPECTROMETRY, 2002, 37 (08) :848-853
[4]   Simple method for the assay of clindamycin in human plasma by reversed-phase high-performance liquid chromatography with UV detector [J].
Cho, SH ;
Im, HT ;
Park, WS ;
Ha, YH ;
Choi, YW ;
Lee, KT .
BIOMEDICAL CHROMATOGRAPHY, 2005, 19 (10) :783-787
[5]   Does the dose matter? [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S233-S237
[6]   TISSUE PENETRATION OF CLINDAMYCIN IN DIABETIC FOOT INFECTIONS [J].
DUCKWORTH, C ;
FISHER, JF ;
CARTER, SA ;
NEWMAN, CL ;
COGBURN, C ;
NESBIT, RR ;
WRAY, CH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (04) :581-584
[7]   Determination of clindamycin in human plasma by high-performance liquid chromatography using coupled columns [J].
Fieger-Büschges, H ;
Schüssler, G ;
Larsimont, V ;
Blume, H .
JOURNAL OF CHROMATOGRAPHY B, 1999, 724 (02) :281-286
[8]   COMPARATIVE-STUDY OF BIOAVAILABILITIES AND PHARMACOKINETICS OF CLINDAMYCIN IN HEALTHY-VOLUNTEERS AND PATIENTS WITH AIDS [J].
GATTI, G ;
FLAHERTY, J ;
BUBP, J ;
WHITE, J ;
BORIN, M ;
GAMBERTOGLIO, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1137-1143
[9]   Update on clindamycin in the management of bacterial, fungal and protozoal infections [J].
Guay, David .
EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (14) :2401-2444
[10]   DETERMINATION OF CLINDAMYCIN IN PLASMA OR SERUM BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION [J].
LAFOLLETTE, G ;
GAMBERTOGLIO, J ;
WHITE, JA ;
KNUTH, DW ;
LIN, ET .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1988, 431 (02) :379-388